Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7230273 | 0.81 | OPRL1 (0.44) | NPSR1HSD11B1OPRL1OPRM1ALDH1A1 | |
| SCHEMBL7689219 | 0.81 | CHRNB2 (0.32) | MEN1KMT2A | |
| SCHEMBL7686941 | 0.81 | CHRNB2 (0.34) | OPRL1MEN1KMT2A | |
| SCHEMBL22629246 | 0.77 | HSD11B1 (0.40) | NPSR1HSD11B1OPRL1OPRM1ALDH1A1 | |
| SCHEMBL7688352 | 0.76 | HSD11B1 (0.39) | NPSR1HSD11B1OPRL1OPRM1CHRM2 | |
| SCHEMBL7228426 | 0.76 | GAA (0.44) | NPSR1HSD11B1OPRL1OPRM1ALDH1A1 | |
| SCHEMBL7221945 | 0.74 | SMN1; SMN2 (0.41) | NPSR1HSD11B1OPRL1ALDH1A1GAA | |
| SCHEMBL7689198 | 0.74 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL7229908 | 0.71 | NPSR1 (0.40) | NPSR1HSD11B1OPRL1OPRM1ALDH1A1 | |
| SCHEMBL22629830 | 0.71 | HSD11B1 (0.40) | NPSR1HSD11B1OPRL1OPRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020061913-A1 | Bicyclic amine derivatives | SYNGENTA LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| US-6291474-B1 | COMBATING AND CONTROLLING INSECT, ACARINE OR NEMATODE PESTS | ZENECA LIMITED (GB) | 2001-09-18 | — | — | US | disclosed |
| US-6177442-B1 | INSECTICIDES; PESTICIDES; MITICIDES; NEMATOCIDES | ZENECA LIMITED (GB) | 2001-01-23 | — | — | US | disclosed |
| US-5968947-A | INSECTICIDES, ACARICIDES, NEMATOCIDES | ZENECA LIMITED (GB) | 1999-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061913-A1 | Bicyclic amine derivatives | ADRA1D, TAAR1, ADRA1A | NPSR1 231/4885HSD11B1 1948/4885OPRL1 497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.